Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tricyclic compounds, their production and use

a technology of tricyclic compounds and tricyclic compounds, applied in heterocyclic compound active ingredients, biocide, organic chemistry, etc., can solve the problems of unavoidable adverse drug reaction, inability to use pgi.sub.2 chemically and biologically stable enough, and inability to obtain information on the relation of known tricyclic compounds to the affinity of pgi.sub.2 receptors

Inactive Publication Date: 2002-01-17
TAKEDA PHARMA CO LTD
View PDF0 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PGI.sub.2 is by no means chemically and biologically stable enough for use as a medicine.
Moreover, it is not clear-cut in the desired action or actions versus other actions, thus unavoidably inducing adverse drug reactions.
Meanwhile, no information is available on the relation of those known tricyclic compounds to the affinity for PGI.sub.2 receptors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tricyclic compounds, their production and use
  • Tricyclic compounds, their production and use
  • Tricyclic compounds, their production and use

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

Ethyl [(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)oxy]acetate

[0303] To a solution of 3,4-dihydro-5-hydroxy-1(2H)-naphthalenone (8.20 g, 50.6 mmol) in N,N-dimethylformamide (80 mL) was added sodium hydride (60% dispersion in liquid paraffin, 2.22 g, 55.6 mmol) at 0.degree. C. and the mixture was stirred at that temperature for 10 minutes. Then, ethyl bromoacetate (9.29 g, 55.6 mmol) was added and the mixture was further stirred at room temperature for 30 minutes. This reaction mixture was poured in water (80 mL) and extracted with 2 portions of ethyl acetate. The organic layers were pooled, washed with water, dried over anhydrous magnesium sulfate (MgSO.sub.4), and filtered, and the filtrate was concentrated under reduced pressure. The residue was crystallized from hexane-diisopropyl ether to provide 8.40 g of the title compound. Yield 67%. m.p. 58-60.degree. C.

[0304] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.30 (3H, t, J=7.2 Hz), 2.04-2.23 (2H, m), 2.60-2.71 (2H, m), 3.00 (2H, t, J=6.2 Hz),...

reference example 2

Ethyl [(2,3-dihydro-1-oxo-1H-inden-4-yl)oxy]acetate

[0305] Using 2,3-dihydro-4-hydroxy-1H-inden-1-one, the procedure of Reference Example 1 was otherwise repeated to synthesize the title compound. Yield 70%. m.p. 91-93.degree. C. (hexane-diisopropyl ether)

[0306] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.31 (3H, t, J=7.2 Hz), 2.66-2.74 (2H, m), 3.10-3.18 (2H, m), 4.28 (2H, q, J=7.2 Hz), 4.73 (2H, s), 6.92 (1H, dd, J=7.6, 1.0 Hz), 7.26-7.44 (2H, m).

reference example 3

Ethyl [(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]acetate

[0307] Using 3,4-dihydro-6-hydroxy-1(2H)-naphthalene, the procedure of Reference Example 1 was otherwise repeated to synthesize the title compound. Yield 89%. m.p. 39-41.degree. C. (hexane-diisopropyl ether)

[0308] .sup.1H-NMR (CDCl.sub.3) .delta.: 1.31 (3H, t, J=7.4 Hz), 2.03-2.21 (2H, m), 2.57-2.66 (2H, m), 2.87-2.96 (2H, m), 4.29 (2H, q, J=7.4 Hz), 4.68 (2H, s), 6.73 (1H, d, J=2.4 Hz), 6.82 (1H, dd, J=8.8, 2.6 Hz), 8.02 (1H, dd, J=8.8, 2.6 Hz).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
reaction timeaaaaaaaaaa
reaction timeaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

A compound of the formula: wherein R1 is H or a substituent; m is 1-3; Ar is an aromatic group which may be substituted; X is a bond or a divalent straight-chain group having 1-6 atoms which may be substituted; Y is -S-, -O-, or -N(R2)- (R2 is H or a substituent group), Z is -N= or -C(R3)= (R3 is H or a hydrocarbon group), ring A is a benzene ring; ring B is a 5- to 7-membered ring which may be substituted, or a salt thereof is useful for eliciting a prostaglandin I2 receptor agonistic effect.

Description

[0001] The present invention relates to tricyclic compounds having very satisfactory prostaglandin I.sub.2 receptor agonistic activity, their production, intermediates and use.[0002] It is known that prostaglandin I.sub.2 (PGI.sub.2) is a substance which is biosynthesized from arachidonic acid through prostaglandin H.sub.2 (PGH.sub.2) and has potent platelet aggregation inhibitory activity, vasodilative activity, lipid deposition inhibitory activity, and leukocyte activation inhibitory activity. As such, PGI.sub.2 is considered to be effective in the treatment of peripheral vascular diseases (e.g. peripheral embolism, vibration syndrome, Raynaud's disease, etc.), systemic lupus erythematosus, post-PTCA (percutaneous transluminal coronary angioplasty) arterial reobliteration / restenosis, atherosclerosis, thrombosis, diabetic neuropathy, hypertension, ischemic diseases (e.g. cerebral infarction, myocardial infarction, etc.), transient ischemic attack, and glomerulonephritis.[0003] Mean...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D277/60C07D277/84C07D513/04
CPCC07D277/60C07D277/84C07D513/04
Inventor OHKAWA, SHIGENORISETOH, MASAKITERASHITA, ZEN-ICHI
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com